The results indicate that ARL4C could be a “switch” between the EGFR path and the JAK2/STAT5/β-catenin path to maintain the proliferation, migration, and invasion of cancer cells when cells are exposed to Erlotinib and EGFR path is blocked. Here, STAT5A is linked to cancer.